22-MULTI-49-OM-PMC: OM-GRPR1-02, A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ???Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Grants and Contracts Details

StatusActive
Effective start/end date9/15/227/10/23

Funding

  • Medpace Inc: $15,331.00